

July 2018

## Corporate News



- We successfully raised \$438M in our latest round of equity financing, at a \$12B pre-money valuation
- This round brings our total amount raised to date to over \$650M

## Osteoarthritis (OA) Program Update



- We completed a 6-month, 700-patient Phase 2b clinical trial
- Previously, we completed a 6-month, 61-patient Phase 1 clinical trial, and a 12-month, 455-patient Phase 2 clinical trial

## Oncology (ONC) Program Update



- We completed safety reviews of the first two dose groups in a Phase 1 clinical trial for advanced solid tumors
- The Phase 1 trial is currently enrolling for higher dose groups